Exploring RG002C0106 in people with varying kidney function
Part of Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests a new medicine, RG002C0106, to see how it is processed in people with normal or mildly to moderately reduced kidney function. It helps researchers understand how kidney function affects the drug, which is important for future dosing recommendations.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 60 years old.
- Your body mass index (BMI) is between 19.0 and 32.0, and you weigh at least 50 kg (men) or 45 kg (women).
- Your kidney function is either normal or mildly to moderately reduced (based on a blood test called eGFR).
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use effective birth control for 6 months after the last dose.
- You do not have certain infections like hepatitis B, C, HIV, or syphilis, and you have no active infection (like a cold or flu) in the last 4 weeks.
- You have never had a kidney transplant, are not on dialysis, and have not had your spleen removed.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This phase 2a trial tests an experimental drug called RG002C0106 in people with primary IgA nephropathy. The goal is to see if the drug can reduce protein in the urine and protect kidney function.
This trial tests an experimental drug (SC0062 capsule) for people with IgA nephropathy who have protein in their urine. It aims to see if the drug can help reduce kidney damage when added to standard treatments like blood pressure medications.
This trial tests an experimental tablet, HSK39297, for people with IgA nephropathy, a kidney disease. It aims to see if the drug is safe and can help reduce protein in the urine, which is a sign of kidney damage.
This study continues treatment with an experimental medicine called HSK39297 for people with IgA nephropathy, a condition where the immune system damages the kidneys. The trial will track how safe and effective the medicine is over time in people who already completed an earlier study.
This study tests an experimental drug called MY008211A for people with IgA nephropathy (a kidney disease). It aims to see if it can safely reduce protein in the urine and protect kidney function.
This trial tests an experimental drug called ADX-038 for people with certain types of kidney disease that are driven by the complement system (a part of the immune system). The study aims to see if ADX-038 can help slow down or improve kidney function.
Hear when a new IgA Nephropathy (IgAN) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.